{
    "title": "Novartis' Sandoz targets biosimilar version of J&J drug in Samsung deal",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12503383/Novartis-Sandoz-targets-biosimilar-version-J-J-drug-Samsung-deal.html",
    "date": "2023-09-11",
    "keywords": [
        "sandoz",
        "stelara",
        "deal",
        "samsung",
        "company",
        "margin",
        "frankfurt",
        "unit",
        "monday",
        "version",
        "johnson",
        "drug",
        "collaboration",
        "bioepis",
        "month",
        "transaction",
        "investment",
        "market",
        "biotech",
        "patent",
        "protection",
        "development",
        "programme",
        "biosimilar",
        "product",
        "europe",
        "immunology",
        "patient",
        "offering",
        "highvalue",
        "ceo",
        "richard",
        "saynor",
        "disease",
        "plaque",
        "psoriasis",
        "arthritis",
        "colitis",
        "profitability",
        "core",
        "profit",
        "year",
        "marketing",
        "cost",
        "inflation",
        "novartis",
        "spinoff",
        "meeting",
        "sept",
        "day",
        "trading",
        "reporting",
        "burger",
        "miranda",
        "murray",
        "michael",
        "perry"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}